Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post transaction

Citius Pharmaceuticals，Inc.将获得Citius Oncology，Inc.的6.75亿美元股权，并在公开上市的Citius Oncology，Inc.交易后保留约90%的多数控制权

Transaction anticipated to close in the first half of 2024

交易预计将于2024年上半年结束

CRANFORD, N.J. and NEW YORK, Oct. 24, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ('Citius Pharma' or the 'Company') (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, and TenX Keane Acquisition ('TenX') (NASDAQ: TENKU), a publicly traded special purpose acquisition company (SPAC), today announced that they have entered into a definitive agreement, dated October 23, 2023, for a proposed merger of TenX and Citius Pharma's wholly owned oncology subsidiary that will continue as a public company listed on the Nasdaq exchange.

CRANFORD，N.J。和纽约，2023年10月24日/PRNewswire/-Citius Pharmaceuticals，Inc。（'Citius Pharma'或'公司'）（纳斯达克：CTXR），一家开发和商业化一流重症监护产品的生物制药公司，以及公开交易的特种收购公司TenX-Keane收购（'TenX'）（纳斯达克：TENKU），今天宣布，他们已于2023年10月23日就TenX和Citius Pharma的合资肿瘤子公司的拟议合并达成明确协议，该子公司将继续作为纳斯达克交易所上市的上市公司。

The newly combined public company will be named Citius Oncology, Inc. ('Citius Oncology'). Upon closing, pursuant to the terms of the merger agreement, Citius Pharma would receive 67.5 million shares in Citius Oncology at $10 per share and retain majority ownership of approximately 90%. The transaction has been approved by the Board of Directors of both companies and is expected to close in the first half of 2024. .

新合并的上市公司将被命名为Citius Oncology，Inc。（'Citius Oncology'）。结束后，根据合并协议条款，Citius Pharma将以每股10美元的价格获得6750万股Citius Oncology股份，并保留约90%的多数所有权。该交易已获得两家公司董事会的批准，预计将于2024年上半年结束。

CITIUS ONCOLOGY OVERVIEW

CITIUS肿瘤学概述

Citius Oncology will serve as a platform to develop and commercialize novel targeted oncology therapies. The company is seeking approval from the U.S. Food and Drug Administration (FDA) of LYMPHIR for an orphan indication in the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma.

Citius Oncology将成为开发和商业化新型靶向肿瘤疗法的平台。该公司正在寻求LYMPHIR的美国食品和药物管理局（FDA）批准用于治疗持续性或复发性皮肤T细胞淋巴瘤（CTCL）（一种罕见的非霍奇金淋巴瘤）的孤儿适应症。

Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing and is underserved by existing therapies. If approved, LYMPHIR would be unique as the only IL-2 receptor targeted CTCL therapy, offering a novel option to patients cycling through multiple treatments. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning..

管理层估计，LYMPHIR的初始市场目前超过4亿美元，正在增长，现有疗法服务不足。如果获得批准，LYMPHIR将是唯一一种针对IL-2受体的CTCL治疗方法，为通过多种治疗循环的患者提供新的选择。强大的知识产权保护涵盖孤儿药指定，复杂的技术，商业秘密以及免疫肿瘤学作为检查点抑制剂联合治疗的未决专利，将进一步支持Citius oncology的竞争定位。。

Preparations are underway for a Biologics License Application (BLA) resubmission in early 2024. If approved, LYMPHIR could be commercially available as early as the second half of 2024 for the treatment of CTCL. Additional value creating opportunities in larger markets include potential indications in peripheral T-cell lymphoma or as a combination therapy with CAR-T and PD-1 inhibitors, and in markets outside the U.S.

2024年初正在准备生物制剂许可证申请（BLA）重新提交。如果获得批准，LYMPHIR可早在2024年下半年用于治疗CTCL。在更大市场上创造额外价值的机会包括外周T细胞淋巴瘤的潜在适应症或与CAR-T和PD-1抑制剂的联合治疗，以及美国以外的市场。

Currently, two investigator-initiated trials are underway to explore LYMPHIR's potential as an immuno-oncology combination therapy..

目前，正在进行两项由研究者发起的试验，以探索LYMPHIR作为免疫肿瘤学联合治疗的潜力。。

The transaction is expected to provide Citius Oncology with improved access to the public equity markets and thereby facilitate the commercialization of LYMPHIR and position the company to explore additional value creating opportunities more fully.

预计该交易将为Citius Oncology提供更好的股权市场准入机会，从而促进LYMPHIR的商业化，并使公司能够更充分地探索额外的价值创造机会。

CITIUS PHARMA AND TENX COMMENTS

CITIUS PHARMA和TENX评论

'We believe this transaction will allow us to unlock the value of LYMPHIR, and solidly position Citius Pharma to advance our diversified pipeline. This transaction will enable Citius Oncology, with access to the broader capital markets, to better support the successful commercialization of LYMPHIR, if approved, and explore additional potential targeted oncology therapies.

“我们相信这项交易将使我们能够释放LYMPHIR的价值，并坚定地支持Citius Pharma推进我们多元化的渠道。这项交易将使Citius Oncology能够进入更广泛的资本市场，更好地支持LYMPHIR的成功商业化（如果获得批准），并探索其他潜在的靶向肿瘤治疗。

Our majority ownership position and shared services agreement ensures that the Citius Pharma management team will remain fully engaged with the development and commercialization efforts at Citius Oncology. As previously announced, the Company is in the process of formulating a plan of distribution of a portion of the shares of Citius Oncology to its shareholders.

我们的多数所有权和共享服务协议确保了Citius Pharma管理团队将继续充分参与Citius Oncology的开发和商业化工作。如前所述，公司正在制定将Citius Oncology部分股份分配给股东的计划。

At Citius Pharma, we intend to focus on completing the Mino-Lok trial and continuing to evaluate next steps with our Halo-Lido program,' stated Leonard Mazur, Chairman and CEO of Citius Pharma..

在Citius Pharma，我们打算专注于完成Mino-Lok试验，并继续评估我们的Halo Lido计划的后续步骤，'Citius Pharma主席兼首席执行官Leonard Mazur说。。

'We are very pleased to announce the proposed merger with Citius Oncology,' said Mr. Xiaofeng Yuan, Chairman and CEO of TenX. 'After undertaking a comprehensive process with external advisors to explore and evaluate numerous potential business combination targets, our board and management team believe that this transaction with Citius Oncology represents the best opportunity to create substantial value for our stockholders.

“我们非常高兴地宣布提议与Citius Oncology合并，”TenX主席兼首席执行官袁晓峰先生说在与外部顾问进行全面的流程以探索和评估众多潜在的业务组合目标之后，我们的董事会和管理团队认为，与Citius Oncology的这项交易是为我们的股东创造实质性价值的最佳机会。

This business combination, if consummated, will result in TenX investors owning an equity stake in a company that is focused on developing and commercializing LYMPHIR to improve the lives of patients with CTCL and additional potential upside from combinations with other drugs as immuno-oncology therapies with even larger addressable markets.

如果这项业务组合完善，将导致TenX投资者拥有该公司的股权，该公司专注于开发和商业化LYMPHIR以改善CTCL患者的生活，以及与其他药物联合作为免疫肿瘤疗法的额外潜在收益。更大的可寻址市场。

We are thrilled to support Citius Oncology at an inflection point in its development and to provide an avenue for Citius to expeditiously meet its development milestones.'.

我们很高兴在Citius肿瘤学发展的一个拐点为其提供支持，并为Citius迅速实现其发展里程碑提供了一条途径。

THE PROPOSED MERGER AGREEMENT

拟议的合并协议

Pursuant to the proposed agreement, TenX will acquire Citius Pharma's wholly owned subsidiary via a merger, with the newly combined publicly traded company to be named Citius Oncology, Inc. In the transaction, all shares of Citius Pharma's wholly owned subsidiary would be converted into the right to receive common stock of Citius Oncology.  As a result, upon closing, Citius Pharma would receive 67.5 million shares of common stock of Citius Oncology which, at an implied value of $10.00 per share, would be $675 million in equity of Citius Oncology, before fees and expenses.

根据拟议协议，TenX将通过合并收购Citius Pharma的国有子公司，与新合并的上市公司名为Citius Oncology，Inc。在该交易中，Citius Pharma的合资子公司的所有股份将转换为有权接收Citius Oncology的普通股。因此，截止时，Citius Pharma将获得6750万股Citius Oncology普通股，在费用和费用之前，其隐含价值为每股10.00美元，将为Citius Oncology股权6.75亿美元。

As part of the transaction, Citius Pharma will contribute $10 million in cash to Citius Oncology. An additional 12.75 million existing options will be assumed by Citius Oncology..

作为交易的一部分，Citius Pharma将向Citius Oncology提供1000万美元的现金。Citius Oncology将承担额外的1275万现有选项。。

At closing, any cash remaining in TenX's trust account along with the cash provided by Citius Pharma will be contributed to Citius Oncology to support ongoing operations and planned commercialization efforts. References to available cash from the TenX trust account and retained transaction proceeds are subject to any redemptions by the public stockholders of TenX and payment of transaction fees and expenses..

结束时，TenX信托账户剩余的任何现金以及Citius Pharma提供的现金将向Citius Oncology提供资金，以支持正在进行的运营和计划的商业化工作。从TenX信托账户获得的可用现金和保留的交易收益取决于TenX公共股东的任何赎回以及交易费用和支出的支付。。

Upon closing, Citius Oncology will operate under a shared services agreement with Citius Pharma, with fees payable quarterly to Citius Pharma, for the services of several key members of the Citius Pharma team, led by Leonard Mazur, Chief Executive Officer, Jaime Bartushak, Chief Financial Officer and Dr.

结束后，Citius Oncology将根据与Citius Pharma签订的共同服务协议进行运营，每季度向Citius Pharma支付费用，用于由Jaime Bartushak首席执行官Leonard Mazur领导的Citius Pharma团队几个关键成员的服务。财务官和博士。

Myron Czuczman, Chief Medical Officer. Myron Holubiak will serve as Executive Vice Chairman of the Citius Oncology Board of Directors.   .

Myron Czuczman，首席医疗官。Myron Holubiak将担任Citius肿瘤委员会执行副主席。   .

The transaction, which has been unanimously approved by both Boards of Directors of Citius Pharma and TenX, is subject to approval by stockholders of TenX and other customary closing conditions. Citius Pharma, as the sole holder of Citius Oncology common stock, has approved the transaction. The proposed business combination is expected to be completed in the first half of 2024..

该交易已获得Citius Pharma和TenX董事会的一致批准，并需要TenX股东和其他习惯性关闭条件的批准。作为Citius Oncology普通股的唯一持有人，Citius Pharma已批准该交易。拟议的业务组合预计将于2024年上半年完成。。

A more detailed description of the transaction terms and a copy of the business combination agreement will be included in a Current Report on Form 8-K to be filed by each of Citius Pharma and TenX with the United States Securities and Exchange Commission ('SEC'). In connection with the transaction, TenX intends to file a registration statement (which will contain a proxy statement/prospectus) with the SEC..

交易条款的更详细描述和业务组合协议的副本将包含在表格8-K的当前报告中，该报告由Citius Pharma和TenX各自与美国证券交易委员会（'SEC'）。关于该交易，TenX打算向SEC提交注册声明（其中将包含代理声明/IPO）。。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不得构成出售或征求购买本文所述任何证券的报价，也不得在任何州或管辖区出售这些证券，在根据任何此类州或管辖区的证券法进行注册或鉴定之前，此类报价，征求或销售将是非法的。。

CITIUS PHARMA AND TENX STOCKHOLDERS AND OTHER INTERESTED PERSONS ARE ADVISED TO READ, ONCE AVAILABLE, THE REGISTRATION STATEMENT AND THE PRELIMINARY PROXY STATEMENT/PROSPECTUS AND ANY AMENDMENTS THERETO AND, ONCE AVAILABLE, THE DEFINITIVE PROXY STATEMENT/PROSPECTUS IN CONNECTION WITH THE BUSINESS COMBINATION, BECAUSE THESE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT CITIUS PHARMA, TENX, CITIUS ONCOLOGY AND THE PROPOSED MERGER..

建议CITIUS PHARMA和TENX股东和其他感兴趣的人一旦可用，阅读注册声明和初步代理声明/IPO以及对其的任何修改，以及一旦可用，与业务组合相关的最终代理声明/IPO，因为这些文件将包含有关CITIUS PHARMA，TENX，CITIUS ONCOLOGY和拟议的合并。。

ADVISORS

顾问

Maxim Group LLC is acting as exclusive financial advisor to Citius Pharma and Newbridge Securities Corporation is acting as exclusive financial advisor to TenX. Wyrick Robbins Yates & Ponton LLP is acting as legal advisor to Citius Pharma. The Crone Law Group P.C. is acting as legal advisor to TenX..

Maxim Group LLC是Citius Pharma的独家财务顾问，纽布里奇证券公司是TenX的独家财务顾问。Wyrick Robbins-Yates＆Ponton LLP担任Citius Pharma的法律顾问。Crone Law Group P.C.正在担任TenX的法律顾问。。

IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION AND WHERE TO FIND IT

关于建议的业务组合以及在哪里找到它的重要信息

In connection with the proposed business combination, TenX intends to file a registration statement on Form S-4 that will include a proxy statement of TenX and a prospectus of Citius Oncology. The proxy statement/prospectus will be sent to all TenX stockholders. Before making any voting decision, securities holders of TenX are urged to read the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed business combination as they become available because they will contain important information about the proposed business combination and the parties to the proposed business combination. .

关于拟议的业务组合，TenX打算在表格S-4上提交注册声明，其中将包括TenX的代理声明和Citius Oncology的IPO。代理声明/IPO将发送给所有TenX股东。在作出任何投票决定之前，敦促TenX的证券持有人阅读代理声明/IPO以及提交或将与SEC一起提交的与拟议业务组合相关的所有其他相关文件，因为它们将包含有关拟议业务的重要信息组合和拟议业务组合的各方。 .

Investors and securities holders will be able to obtain free copies of the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by TenX and Citius Pharma through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by Citius Pharma may be obtained free of charge from Citius Pharma's website at www.citiuspharma.com, or by written request to Citius Pharmaceuticals, Inc., 11 Commerce Drive, 1st Floor, Cranford, New Jersey 07016, Attention Chief Financial Officer.

投资者和证券持有人将能够通过SEC在www.SEC.gov维护的网站免费获取代理声明/IPO以及TenX和Citius Pharma提交或将向SEC提交的所有其他相关文件的免费副本。此外，Citius Pharma提交的文件可以从Citius Pharma的网站www.citiuspharma.com免费获得，或书面请求给新泽西州克兰福德市一楼11 Commerce Drive的Citius Pharmaceuticals，Inc。07016，Attention首席财务官。

The documents filed by TenX may be obtained free of charge by written request to TenX Keane Acquisition, 420 Lexington Avenue, Suite 2446, New York, New York 10170..

由TenX提交的文件可以通过书面请求免费获得，TenX Keane Acquisition，420 Lexington Avenue，Suite 2446，New York，New York 10170。。

PARTICIPANTS IN THE SOLICITATION

参与征集

Citius Pharma and Tenx and certain of their respective directors, executive officers, and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitations of proxies from TenX's shareholders in connection with the proposed transaction. Information regarding Citius Pharma's directors and executive officers is available in its definitive proxy statement on Schedule 14A for the 2023 annual meeting of stockholders, which was filed with the SEC on December 22, 2022.

根据SEC规则，Citius Pharma和Tenx及其某些各自的董事，执行官以及管理层和员工的其他成员可被视为参与Tenx股东就拟议交易征集代理人的参与者。关于Citius Pharma的董事和执行官的信息可以在2023年12月22日提交给SEC的2023年股东年会时间表14A的最终代理声明中找到。

Information about TenX's directors and executive officers and their ownership of TenX's securities is set forth in TenX's filings with the SEC, including TenX's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on April 17, 2023. To the extent that holdings of TenX's securities have changed since the amounts printed in TenX's Annual Report, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC..

有关TenX董事和执行官及其对TenX证券所有权的信息，请参阅TenX与SEC的文件，包括TenX截至2022年12月31日的10-K表格年度报告，该报告于4月17日提交给SEC。2023年。如果自TenX年度报告中印刷的金额以来TenX证券的持有量发生了变化，则此类变化已经或将反映在向SEC提交的表格4中的所有权变更声明中。。

Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests will be included in the proxy statement/prospectus when it becomes available. Shareholders, potential investors, and other interested persons in respect of Citius Pharma and TenX should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions.

有关代理征集参与者的其他信息及其直接和间接利益的描述将在代理声明/承销说明书可用时包含在内。Citius Pharma和TenX的股东，潜在投资者和其他感兴趣的人在做出任何投票或投资决定之前，应仔细阅读代理声明/IPO。

You may obtain free copies of these documents from the sources indicated above..

您可以从上述来源获得这些文件的免费副本。。

About Citius Oncology, Inc.

关于Citius Oncology，Inc。

Citius Oncology is a late-stage pharmaceutical company focused on developing and commercializing targeted oncology therapies.  Its strategy centers on achieving a market leading position by advancing innovative therapies with reduced development and clinical risks, and leveraging competitive advantages supported by intellectual property and regulatory exclusivity protection.

Citius Oncology是一家专注于开发和商业化靶向肿瘤疗法的后期制药公司。其战略的重点是通过推进发展和临床风险降低的创新疗法，并利用知识产权和监管排他性保护支持的竞争优势，实现市场领先地位。

This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies..

这包括以前批准的药物的新配方，具有大量现有的安全性和有效性数据或扩大的批准治疗适应症。。

Citius Oncology's lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. Management believes the market for LYMPHIR for CTCL, estimated to exceed $400 million, is attractive, growing and underserved by existing treatments.

Citius Oncology的主要候选产品是LYMPHIR，一种工程化的IL-2白喉毒素融合蛋白，用于治疗持续性或复发性CTCL患者，这是一种罕见的非霍奇金淋巴瘤。管理层认为，LYMPHIR的CTCL市场估计超过4亿美元，具有吸引力，增长和现有治疗服务不足。

On July 28, 2023, the FDA issued a complete response letter (CRL) in response to the LYMPHIR BLA. The FDA is requiring enhanced product testing and additional controls agreed to with the FDA during the market application review.  There were no concerns relating to the safety and efficacy of the clinical data package submitted with the BLA, or the proposed prescribing information.

2023年7月28日，FDA发布了一份完整的回复信（CRL），以回应LYMPHIR BLA。FDA要求在市场申请审查期间加强产品测试和与FDA达成一致的其他控制措施。没有人担心与BLA一起提交的临床数据包的安全性和有效性，或者提出的处方信息。

In September 2023, Citius Pharma announced that the FDA has agreed with the plans to address the requirements outlined in the CRL. This guidance has clarified the path forward in completing the necessary activities to support the resubmission of the BLA for LYMPHIR. The BLA resubmission is anticipated in early 2024..

2023年9月，Citius Pharma宣布FDA已同意解决CRL中概述的要求的计划。本指南阐明了完成必要活动以支持BLA重新提交LYMPHIR的前进道路。BLA重新提交预计在2024年初。。

Citius Oncology was founded in August 2021 as Citius Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Citius Pharma and began operations in April 2022. The corporate name was changed to Citius Oncology, Inc. in May 2023.

Citius Oncology成立于2021年8月，是特拉华州Citius收购公司和Citius Pharma的合资子公司，于2022年4月开始运营。公司名称于2023年5月更改为Citius Oncology，Inc。

About Citius Pharmaceuticals, Inc.

关于Citius制药公司。

Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company's diversified pipeline includes two late-stage product candidates.

Citius Pharma是一家后期生物制药公司，致力于一流重症监护产品的开发和商业化，重点关注肿瘤学，辅助癌症护理中的抗感染药物，独特的处方产品和干细胞疗法。该公司的多元化管道包括两个后期产品候选人。

Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections, is enrolling patients in a Phase 3 Pivotal superiority trial and was granted Fast Track designation by the FDA. Citius Pharma is preparing to resubmit the Biologics License Application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in CTCL, in early 2024.

Mino-Lok®是一种用于治疗导管相关血流感染患者的抗生素锁定解决方案，正在招募患者参加3期关键优势试验，并获得FDA的快速通道认证。Citius Pharma正在准备于2024年初重新提交LYMPHIR的生物制剂许可申请，LYMPHIR是一种新型IL-2R免疫疗法，用于CTCL的初始适应症。

LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. At the end of March 2023, Citius Pharma completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com..

LYMPHIR获得FDA指定的用于治疗CTCL和PTCL的孤儿药。2023年3月底，Citius Pharma完成了CITI-002（Halo Lido）的2b期临床试验，这是一种用于缓解痔疮的局部制剂。欲了解更多信息，请访问www.citiuspharma.com。。

About TenX Keane Acquisition

关于TenX Keane收购

TenX Keane Acquisition is a blank check company, also commonly referred to as a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.

TenX Keane收购是一家空白检查公司，通常也称为特殊用途收购公司（SPAC），旨在实现与一个或多个公司的合并，股权交换，资产收购，股权购买，重组或类似业务组合业务或实体。

TenX is led by Xiaofeng Yuan, Chairman and Chief Executive Officer, and Taylor Zhang, Chief Financial Officer, who are growth-oriented executives with a long track record of value creation across industries. .

TenX由主席兼首席执行官袁晓峰和首席财务官Taylor Zhang领导，他们是以增长为导向的高管，在各行业拥有悠久的价值创造记录。 .

Forward-Looking Statements

前瞻性声明

This press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the benefits of the transaction, the anticipated timing of the transaction, the products offered by Citius Pharma and Citius Oncology and the markets in which each operates, and Citius Pharma and Citius Oncology's projected future results.

本新闻稿可能包含1933年“证券法”第27A条和1934年“证券交易所法”第21E条含义内的“前瞻性声明”，包括关于交易利益，交易预期时间，Citius Pharma和Citius Oncology提供的产品以及各自经营的市场，以及Citius Pharma和Citius Oncology预计的未来成果。

These forward-looking statements generally are identified by the words 'believe,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.

这些前瞻性陈述通常由“相信”，“项目”，“期望”，“预期”，“估计”，“打算”，“策略”，“未来”，“机会”，“计划”，“可能”，“应该”，“将会”，“将会”，“将会继续”，“可能会导致”和类似的表达。前瞻性陈述是基于当前预期和假设的关于未来事件的预测，预测和其他陈述，因此受到风险和不确定性的影响。

Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including, but not limited to: Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as 'believe,' 'anticipate,' 'estimate,' 'expect,' 'plan,' 'would,' 'should,' and 'may' and other words and terms of similar meaning or use of future dates.

许多因素可能导致实际的未来事件与本文档中的前瞻性陈述有很大不同，包括但不限于：此类陈述是基于我们对影响Citius Pharma的未来事件的期望和信念而做出的。您可以通过使用“相信”，“预期”，“估计”，“期望”，“计划”，“将会”，“应该”和“可能”等词语来识别这些陈述。具有相似含义或使用未来日期的词语和条款。

Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk that the transaction may not b.

前瞻性陈述基于管理层当前的预期，并存在可能对我们的业务，经营成果，财务状况和股票价格产生负面影响的风险和不确定性。可能导致实际结果与当前预期大不相同的因素是：交易可能不是b的风险。

Citius Pharmaceuticals Investor Contact:

Citius Pharmaceuticals投资者联系人：

Ilanit Allen[email protected]

Ilanit Allen[电子邮件保护]

Citius Pharmaceuticals Media Contact:

Citius Pharmaceuticals Media联系人：

STiR-communicationsGreg Salsburg[email protected]

STiR沟通萨尔斯堡[电子邮件保护]

TenX ContactTaylor Zhang[email protected]

TenX ContactTaylor Zhang[电子邮件保护]

SOURCE Citius Pharmaceuticals, Inc.

来源Citius Pharmaceuticals，Inc。